 |
| PRESS RELEASE >> JANUARY 15 - 2009 | ||
PROTOKINETIX INC. (PKTX: OTCBB) Ross Senior, President and CEO of ProtoKinetix Inc. (PKTX), announces the formation of a Joint Venture with Zymes LLC to commercialize a unique new product line. Zymes is a world leader in the production of high quality Co-enzyme Q10, a well recognized and potent anti-oxidant. Zymes’ Co-founder and Chief Scientific Officer, Dr. Bruce Lipshutz, has patented a method for producing water soluble CoQ10 (The Lipshutz Method) which has been proven to increase the absorption into cells and tissues for protection and repair. This Joint Venture will combine the knowledge and expertise of two world renowned sciences from France (Dr. Geraldine Deliencourt) and the United States (Prof. Bruce Lipshutz, U of C, Santa Barbara). Over the last few years extensive tests by PKTX subjected skin cells to harmful oxidative stresses of ultra violet radiation and hydrogen peroxide. The tests showed AAGP™ to be a powerful anti-oxidant, however the combination of these two molecules (AAGP™ and CoQ10) provided significantly greater protection from the harmful oxidative stresses than could otherwise be attained from either molecule acting individually. ProtoKinetix’ news release of January 26, 2006 provides a summary of the dramatic results achieved combining these two molecules for cell and tissue protection. UV radiation and oxidation damage cells, tissues and organs and are major contributors to aging of the skin. The Joint Venture is founded on the unique combination of the molecular structures, bioactivities and health care attributes of PKTX’ AAGP™ and Zymes’ CoQ10. In addition to skin care, other targeted applications include stem cell preservation and survival, ischemia, reperfusion injury and wound healing. The diversity of applications underscores the value of the AAGP™ family of molecules. Ross Senior says, “We are extremely pleased to partner with Zymes and are confident about the success of the venture and the benefits for our shareholders.”
About ProtoKinetix ProtoKinetix, Inc. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP(TM)) for medicine and the biotechnology and cosmetic industries. PKTX is currently in dialog with major corporations and institutions who have contacted the Company about the broad range of applications for AAGP(TM) products. For more information, visit www.protokinetix.com. For more detailed information, please visit our website at: www.protokinetix.com The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission. Company Office: At ProtoKinetix:
|
|
|
HOME - AFGP to AAGP - AAGP TESTS - COMMERCIAL APPLICATIONS - PRESS RELEASES - CONTACT Copyright 2008 © Protokinetix Inc. All rights reserved. | Privacy Policy | Safe Harbor | |
